ACCRETAMAB Trademark

Trademark Overview


On Tuesday, July 6, 2021, a trademark application was filed for ACCRETAMAB with the United States Patent and Trademark Office. The USPTO has given the ACCRETAMAB trademark a serial number of 90812301. The federal status of this trademark filing is REGISTERED as of Tuesday, July 11, 2023. This trademark is owned by Kyowa Kirin Co., Ltd.. The ACCRETAMAB trademark is filed in the Pharmaceutical Products category with the following description:

Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids, hormones in the nature of pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticals, namely, corticosteroids for treatment of hypopitui...
accretamab

General Information


Serial Number90812301
Word MarkACCRETAMAB
Filing DateTuesday, July 6, 2021
Status700 - REGISTERED
Status DateTuesday, July 11, 2023
Registration Number7102836
Registration DateTuesday, July 11, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2023

Trademark Statements


Goods and ServicesHost cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids, hormones in the nature of pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticals, namely, corticosteroids for treatment of hypopituitarism, of congenital adrenal hyperplasia, of rheumatoid arthritis, of rheumatic fever, of crohn's disease, and of chronic active hepatitis; pharmaceuticals, namely, estrogen preparations and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents; pharmaceuticals, namely, cataplasms being medical plasters for the treatment of bruises, lumbago and stiff shoulder; pharmaceuticals, namely, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents in the nature of vitamins for treating vitamin deficiencies, anti-coagulants, enzyme preparations for medical purposes for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, charred drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, moxa in the nature of cone or stick made of ground mugwort leaves for treating peptic ulcers; pharmaceuticals, namely, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; pharmaceuticals, namely, germination controllers and plant rearing agents in the nature of herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; pharmaceuticals, namely, antiseptics, pharmaceutical drugs in the nature of drug delivery agents in the form of coatings for tablets for the treatment of arteriosclerosis, oncostatic drugs in the nature of pharmaceutical products for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs in the nature of pharmaceutical products for the prevention and treatment of parkinsonism, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances and nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases; all the foregoing pharmaceuticals and vaccines comprising monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKyowa Kirin Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTokyo 100-0004
JP

Party NameKyowa Kirin Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 100-0004
JP

Party NameKyowa Kirin Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 100-0004
JP

Trademark Events


Event DateEvent Description
Tuesday, July 11, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, July 11, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, April 25, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 25, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 17, 2023ELECTRONIC RECORD REVIEW COMPLETE
Friday, March 10, 2023ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Tuesday, March 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 14, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 14, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 14, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 31, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 31, 2022NON-FINAL ACTION E-MAILED
Wednesday, August 31, 2022NON-FINAL ACTION WRITTEN
Saturday, July 30, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 16, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 16, 2022NON-FINAL ACTION E-MAILED
Wednesday, February 16, 2022NON-FINAL ACTION WRITTEN
Wednesday, February 9, 2022ASSIGNED TO EXAMINER
Monday, September 20, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Friday, September 17, 2021ASSIGNED TO LIE
Wednesday, July 21, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, September 14, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 9, 2021NEW APPLICATION ENTERED